The interleukin-8 receptor: a potential target for antipsoriatic therapy? Eur J Pharmacol 1994 Jun 13;258(3):269-72
Date
06/13/1994Pubmed ID
8088360DOI
10.1016/0014-2999(94)90490-1Scopus ID
2-s2.0-0028361490 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
Interleukin-8 is assumed to play a central role in the pathogenesis of psoriasis. Since an increased expression of the interleukin-8 receptor has been observed both in polymorphonuclear leukocytes and in affected psoriatic epidermis, we were interested in whether the interleukin-8 receptor could be a molecular target of antipsoriatic compounds. Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected. In addition, the interleukin-8-induced human leukocyte antigen-DR (HLA-DR) expression of keratinocytes was nearly completely blocked by treatment of the cells with these substances. The inhibition of the keratinocyte interleukin-8 receptor and its function by antipsoriatic drugs may contribute to their therapeutic action.
Author List
Kemény L, Kenderessy AS, Olasz E, Michel G, Ruzicka T, Farkas B, Dobozy AAuthor
Edit Olasz MD, PhD Associate Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnthralinCalcitriol
Cells, Cultured
Cyclosporine
Flow Cytometry
HLA-DR Antigens
Humans
Interleukin-8
Keratinocytes
Neutrophils
Psoriasis
Receptors, Interleukin
Receptors, Interleukin-8A
Recombinant Proteins
